Providing patients and customers with
uncompromising quality and value for almost 40 years
Par is a specialty pharmaceutical company that develops, manufacture and markets innovative and cost-effective pharmaceuticals that help improve patient quality of life. Par Pharmaceutical offers a line of high barrier-to-entry generic drugs, while Par Specialty Pharmaceuticals provides niche, innovative brands. Par Sterile Products develops, manufactures and markets both branded and generic aseptic injectable pharmaceuticals.
At Par, our most important resource is the talent and dedication of our nearly 1,900 employees, each of whom is part of a culture that values integrity, customer focus, teamwork and performance. In creating a climate that encourages collaboration, Par has become the partner of choice within its industry and has built a diverse network of strategic partnerships with dozens of companies. Headquartered in Woodcliff Lake, New Jersey, Par has manufacturing and R&D facilities in Chestnut Ridge, New York, Irvine, California, Rochester, Michigan, Stratford, Connecticut and Chennai, India.
|08/04/15||Par Pharmaceutical Begins Shipment of Generic Sodium Edecrin® |
|Company Introduces First Generic Version of the BrandChestnut Ridge, NY, Aug. 4, 2015 – Par Pharmaceutical today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for ethacrynate sodium for injection USP, equivalent to ethacrynic acid 50 mg. Ethacrynate sodium is the generic version of Aton Pharma’s Sodium Edecrin® and is used in the treatment of edema. Par’s ethacrynate sodium for injection USP, 50 mg is... |
|08/03/15||Par Pharmaceutical Announces Second Quarter 2015 Conference Call|
|Chestnut Ridge, NY, August 3, 2015 – Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Friday, August 7, 2015 at 9:00 a.m. EDT to review its results of operations for the second quarter ended June 30, 2015. Par is privately held and currently makes certain financial information available to the public in its filings with the Securities and Exchange Commission and will make certain other information available on its website by following the instructio... |
|07/29/15||Par Pharmaceutical Begins Shipment of Generic Megace® ES|
|Chestnut Ridge, NY, July 29, 2015 – Par Pharmaceutical Companies, Inc. today announced that it has begun shipping the authorized generic version of Par Specialty Pharmaceutical’s Megace® ES (megestrol acetate, USP) oral suspension. Par’s launch of its authorized generic product follows a competitor’s introduction of the first generic version of Megace® ES. Megace® ES oral suspension is a progestin indicated for the treatment of anorexia, cachexia, or an unexplained significant weight... |
|05/27/15||Par Pharmaceutical Receives Favorable Appeals Court Ruling in Generic Exelon® Patch Litigation|
|Chestnut Ridge, NY, May 27, 2015 – Par Pharmaceutical Companies, Inc. today announced that the United States Court of Appeals for the Federal Circuit has upheld the U.S. District Court for the District of Delaware’s earlier ruling that Par’s filing of an Abbreviated New Drug Application for its generic version of Novartis’ Exelon® Patch (rivastigmine transdermal system) does not infringe United States Patent Nos. 6,316,023 or 6,335,031. The appeals court also affirmed the district court’s ... |
|There are currently no events scheduled.|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.